Skip to content
  1. Home
  2. Anti-aging
  3. Leuphasyl

Anti-aging

Leuphasyl

A stabilized enkephalin fragment marketed as a topical, needle-free alternative to neuromuscular-blocking wrinkle treatments — the mechanism is plausible, the human wrinkle-reduction evidence is thin.

Research chemical Anti-aging

Reviewed 2026-09-12
Full name
Pentapeptide-18
Also known as
Pentapeptide-18, Leu-DAP, SNAP-8 alternative, Enkephalin-analog pentapeptide
Regulatory status
Unregulated cosmetic ingredient (not a drug); sold in serums/creams, not injectables. No FDA or EMA drug approval process applies because it isn't marketed as a therapeutic.

Origin

Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu) derived from the endogenous opioid peptide Leu-enkephalin, with a D-amino acid substitution at position 2 to resist enzymatic degradation and extend stability in topical formulations. It is a cosmetic-industry ingredient, not a pharmaceutical.

Mechanism

Proposed to act at the neuromuscular junction interface in skin by binding opioid-receptor-like sites and dampening catecholamine and acetylcholine release, theoretically reducing the frequency and force of the micro-contractions in facial muscles that contribute to expression-line formation. This is distinct from Botox's mechanism (SNARE-protein cleavage) and from Argireline's (SNARE-complex assembly inhibition); Leuphasyl is generally pitched as complementary to both.

Research summary

Evidence

Published data are almost entirely in vitro and in silico: molecular docking/dynamics and spectroscopic studies show Leuphasyl binding to inflammation- and matrix-remodeling targets (MMP-13, TGF-β, TNF-α pathways) and formulation studies confirm it is stable and non-cytotoxic to skin cell lines when delivered in lipid nanocarriers. No randomized, placebo-controlled human trial of Leuphasyl alone measuring wrinkle depth has been located on PubMed; manufacturer-reported efficacy claims are not independently peer-reviewed. By contrast, its usual co-formulant Argireline (acetyl hexapeptide-3) does have a small published RCT showing modest anti-wrinkle effects.

Evidence tier: Research chemical — see the methodology note for how this is assessed.

Citations

Reported benefits

  • Reported softening of expression lines (crow's feet, forehead lines) with regular topical use, per manufacturer and formulation literature
  • Marketed as a synergistic partner to Argireline for combined 'triple mechanism' wrinkle serums
  • Non-injectable, no downtime, compatible with routine skincare layering

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
topicalTypically formulated at 5-10% of a peptide-complex solution, itself included in a finished serum/cream at low single-digit percentages; applied once or twice daily to clean, dry skin, often in combination products with Argireline and/or Matrixyl-type peptides

Side effects

  • Mild irritation or contact sensitivity in a minority of users, as with most concentrated peptide serums
  • No systemic side effects reported given negligible dermal penetration at typical topical concentrations

Safety notes

Safety: Cosmetic peptides at these concentrations have a good short-term dermal safety record, but there is no dedicated long-term human safety dataset for Leuphasyl specifically, and efficacy claims rest almost entirely on industry-funded formulation studies rather than independent clinical trials.
Community & reddit notes (anecdotal — not clinical evidence)

Discussed mainly in skincare/DIY-formulation circles as a budget, non-invasive component of 'peptide facial serums,' almost always stacked with Argireline; users report subtle, gradual softening rather than Botox-like results, and skepticism about marketing claims is common even among enthusiasts.